Cytosorbents (CTSO) Cash from Operations Growth (5y) (2015 - 2026)
Cytosorbents (CTSO) Cash from Operations Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.20 Bn | 175.91 Bn | 6.27 Bn |
| 2 | Stryker | 128.87 Bn | 125.99 Bn | 3.81 Bn |
| 3 | Medtronic | 108.88 Bn | 99.66 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.33 Bn | 66.87 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 47.31 Bn | 43.64 Bn | 1.29 Bn |
| 6 | Dexcom | 28.65 Bn | 27.53 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.40 Bn | 26.11 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.97 Bn | 26.40 Bn | - |
| 9 | Koninklijke Philips | 25.55 Bn | 22.42 Bn | 2.07 Bn |
| 10 | Cytosorbents | 23.46 Mn | 18.66 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.10% |
| Dec 31, 2025 | -35.46% |
| Sep 30, 2025 | 4.73% |
| Jun 30, 2025 | -22.68% |
| Mar 31, 2025 | -1.55% |
| Dec 31, 2024 | 10.71% |
| Sep 30, 2024 | 13.91% |
| Jun 30, 2024 | -8.50% |
| Mar 31, 2024 | -2.65% |
| Dec 31, 2023 | -18.80% |
| Sep 30, 2023 | -14.58% |
| Jun 30, 2023 | -16.06% |
| Mar 31, 2023 | -7.12% |
| Dec 31, 2022 | -67.13% |
| Sep 30, 2022 | -25.27% |
| Jun 30, 2022 | -33.68% |
| Mar 31, 2022 | -32.55% |
| Dec 31, 2021 | -38.46% |
| Sep 30, 2021 | -10.86% |
| Jun 30, 2021 | -1.16% |